Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · VIVO BIO TECH LTD. · 9 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
VIVO BIO TECH LTD.
NSE: VIVOBIOT · BSE: 511509
NSE: VIVOBIOT · BSE: 511509
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Biotechnology
VIVO BIO TECH LTD.
StateQ4 FY26 filed
Last close · 8 Oct 2026₹14.40
Market cap₹0.0k cr
TTM P/E · P/B · EV/EBITDA3.4 · 0.34 · 4.6
VIVO BIO TECH LTD. is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 51 | 52 | 45 | 47 | 53 |
| EBITDA (ex other income) | 16 | 22 | 21 | 21 | 21 |
| margin % | 30.8 | 41.2 | 46.4 | 43.9 | 39.1 |
| Owners' profit | 0 | 3 | 3 | 7 | (2) |
| EPS, as reported (₹) | 1.56 | 1.78 | 1.70 | 4.76 | 0.82 |
| ROE % · ROCE % | 4.8 · 8.6 | 5.1 · 12.5 | 4.6 · 11.9 | 9.3 · 14.1 | (1.8) · 7.2 |
| Debt / equity (x) | 1.47 | 1.20 | 1.34 | 0.69 | 0.72 |
| Cash from operations | 15 | 7 | 16 | 12 | 35 |
| Capex | (51) | (4) | (8) | (0) | (37) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · VIVO BIO TECH LTD. · 9 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10 | 12 | 12 | 12 | 13 | 13 | 14 | 14 |
| Profit before tax | 0 | 6 | 1 | 1 | 1 | 2 | 2 | 0 |
| Net profit | 0 | 5 | 1 | 1 | 1 | 1 | 1 | (5) |
| EPS (₹) | 0.11 | 3.51 | 0.55 | 0.69 | 0.74 | 0.45 | 0.56 | 2.52 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| ANTHEM BIOSCIENCES LTD | 49,127 | 126.9 | 16.15 | 50.7 | 19.5 | 26.6 | — | 42.0 |
| ADVANCED ENZYME TECH LTD | 2,983 | 18.0 | 1.77 | 10.5 | 10.3 | 13.4 | 8.2 | 33.7 |
| CCME GLOBAL LIMITED | 153 | 99.5 | 3.82 | — | (1.8) | (1.8) | — | — |
| VIVO BIO TECH LTD. ◆ | 32 | 3.4 | 0.34 | 4.6 | (1.8) | 3.2 | 0.6 | 31.5 |
| Shree Ganesh Biotech (India) L | 18 | 23.0 | 0.29 | — | 0.6 | 0.8 | — | (7.0) |
| GENOMIC VALLEY BIOTECH LIMITED | 10 | 279.2 | 2.60 | — | 0.8 | 1.0 | — | 40.5 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 3.4 | 31.2 | 3 of 164 | 99% |
| P/B | 0.3 | 3.1 | 5 of 169 | 97% |
| ROCE | 3.3 | 10.7 | 142 of 189 | 25% |
| ROE | (1.8) | 9.5 | 152 of 172 | 12% |
| Debt / Equity | 0.7 | 0.1 | 153 of 172 | 11% |
| EBITDA margin | 31.5 | 17.7 | 32 of 170 | 82% |
| Revenue growth | 15.5 | 15.3 | 83 of 166 | 50% |
| Profit growth | (585.9) | 30.0 | 163 of 164 | 1% |
| Market cap | 32 | 842 | 161 of 187 | 14% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · VIVO BIO TECH LTD. · 9 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 7 Oct 2026 · Vivo Bio Tech files Q2 FY27 dematerialization compliance certificate | compliance | minimal | — | — |
| 30 Sept 2026 · All 4 resolutions passed at 39th AGM with 99.68% approval | board shareholder meetings | medium | — | — |
| 30 Sept 2026 · Vivo Bio Tech 39th AGM outcome: 4 items passed, directors re-appointed | board shareholder meetings | low | — | — |
| 30 Sept 2026 · Vivo Bio Tech 39th AGM: Financials Adopted, 3 Directors Re-appointed | board shareholder meetings | low | — | — |
| 25 Sept 2026 · Trading Window Closure Ahead of Q2 FY26 Results | compliance | minimal | — | — |
| 10 Sept 2026 · Monthly report on physical share transfer re-lodgements for August | compliance | minimal | — | — |
| 9 Sept 2026 · Web-link letter sent to shareholders for FY26 Annual Report and 39th AGM | compliance | minimal | — | — |
| 9 Sept 2026 · Vivo Bio Tech publishes 39th AGM notice in newspapers | compliance | minimal | — | — |
| 8 Sept 2026 · Vivo Bio Tech files FY26 annual report and 39th AGM notice with BSE | board shareholder meetings | medium | — | — |
| 8 Sept 2026 · Vivo Bio Tech 39th AGM on Sep 30, 2026; director re-appointments and FY26 results | board shareholder meetings | low | — | — |
Source: exchange announcements; reaction = close-to-close from the filing's session.
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in